Diabetes
Refine Search
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
Texas-based biopharma Lexicon Pharmaceuticals was trading nearly 36% lower on Friday morning. 1 November 2024
Pharmaceutical
Denmark’s Novo Nordisk bucked a down trending market today, rising 1% on promising research results. 1 November 2024
Pharmaceutical
Shares in Merck & Co were more than 2% lower as New York trading entered its latter half on Thursday. The US pharma giant earlier announced its financial results for the third quarter of 2024, along with its latest guidance for the year as a whole. 31 October 2024
Pharmaceutical
US drugmaker Eli Lilly looked set to lose a whopping $730 million in the stock market value on Wednesday, if its lunchtime position was to be maintained. 30 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first patient dosed in the Phase IIb program. 24 October 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
Pharmaceutical
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Pharmaceutical
Canada-based biotech Sernova (TSX: SVA) has announced key new appointments to its executive leadership team. 15 October 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application (NDA) for dasiglucagon. 10 October 2024
Generics
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
Pharmaceutical
Texas Attorney General Ken Paxton has filed a lawsuit against major pharmaceutical companies, including Eli Lilly (NYSE: LLY), alleging a conspiracy to artificially inflate the prices of insulin by up to 1,000%. 7 October 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Pharmaceutical
Eli Lilly today announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development. 2 October 2024
Biotechnology
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Pharmaceutical
Danish insulin giant Novo Nordisk (NVO: N) posted first-quarter 2011 results, showing that total sales grew 15% to 15,693 billion Danish kroner ($3.07 million), boosted by the company's diabetes drug Victoza (liraglutide),which saw turnover nearly triple to 1.1 billion kroner. 29 April 2011
Generics
Indian drugmaker Lupin (LOPN: BO) yesterday announced via a filing with the Bombay stock exchange that it has entered into a licensing pact for various patents of the cholesterol lowerer drug Antara (fenofibrate) with US health care major Abbott Laboratories (NYSE: ABT) and French independent drugmaker Laboratoires Fournier SA. 27 April 2011
Pharmaceutical
The American Academy of Neurology has issued a new guideline on the most effective treatments for diabetic nerve pain, the burning or tingling pain in the hands and feet that affects millions of people with diabetes. The guideline is published in the April 11, 2011, on-line issue of Neurology , the journal of the American Academy of Neurology, and were presented this week at the American Academy of Neurology's Annual Meeting in Honolulu, Hawaii. 13 April 2011
Pharmaceutical
In what looks to be the last hurdle for Swiss drug major Novartis (NOVN: VX) to take full control of eye care specialist Alcon (NYSE:ACL), the latter's independent shareholders have approved the merger. Under the terms of the merger, Alcon shareholders will receive 2.9228 Novartis shares or American Depositary Shares plus a cash payment of $8.20 for each Alcon share. Completion is subject to approval by the Novartis shareholders, which will vote today (April 80. Following completion of the merger, Alcon will terminate its listing on the New York Stock Exchange. 8 April 2011
Pharmaceutical
French pharmaceutical major Sanofi-Aventis (Euronext: SAN) is considering a significant increase in the production capacity of its Russian insulin factory by 2012, according to local reports. 29 March 2011
Pharmaceutical
French drug major Sanofi-Aventis (Euronext: SAN) has entered into a research collaboration with the USA's Columbia University Medical Center for the development of innovative diabetes medicines. This three-year research collaboration, with the laboratory of Gerard Karsenty, will investigate the role of the osteoblast-secreted peptide, osteocalcin, in diabetes management. 25 March 2011
Pharmaceutical
Levemir (insulin detemir), Danish insulin giant Novo Nordisk's (NVO: N) basal insulin analogue, is an equally efficacious treatment option for two to five year-old children with type 1 diabetes, compared with human basal insulin, but is associated with lower hypoglycaemic risk, according to new clinical trial data just published in Pediatric Diabetes. 24 March 2011
Pharmaceutical
Following a period of mediation, USA-based Depomed (Nasdaq: DEPO) will regain rights to its shingles drug Gralise (gabapentin) from drug major Abbott Laboratories (NYSE: ABT), and will receive a $40 million from the latter. The news saw Depomed's shares rise 3.7% to $9 in after-hours trading yesterday. 18 March 2011
Pharmaceutical
Danish insulin giant Novo Nordisk (NVO: N) said last night that the Chinese State Food and Drug Administration (SFDA) has approved Victoza (liraglutide) for the treatment of type 2 diabetes and the company expects to launch the product in that market during the second quarter of this year. Approval in China comes sooner than expected, as the company had previously anticipated this would come through in the second half of this year. 16 March 2011
Pharmaceutical
There was bad news for privately-held US biotech Tolerx and partner UK pharma giant GlaxoSmithKline (LSE: GSK) on Friday, when they revealed that the Phase III DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes. 14 March 2011
article
The US Food and Drug Administration has accepted for review a New Drug Application for dapagliflozin, an investigational compound for the treatment of adults with type 2 diabetes mellitus, being developed by Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb (NYSE: BMY). 9 March 2011
Pharmaceutical
There was disappointing news yesterday for US drugmakers Eli Lilly (NYSE: LLY), Amylin (Nasdaq: AMLN) and Alkermes (Nasdaq ALKS), when they presented new data from the head-to-head DURATION study comparing their investigational type 2 diabetes drug Bydureon (exenatide, extended-release for injectable suspension, which showed the agent failed to reduce patients' average blood glucose levels as much as Danish insulin giant Novo Nordisk's (NVO: N) already marketed Victoza (liraglutide). 4 March 2011
Pharmaceutical
Growth of the pharmaceutical market in Hong Kong is expected to be steady over the medium term. The market should reach HK$10.56 billion ($1.35 billion) in value at consumer prices by 2014, up from the calculated HK$7.19billion in 2009, according to a new report from Business Monitor International. 2 March 2011
Pharmaceutical
The US affiliate of Japan's largest drugmaker, Takeda Pharmaceutical ((TSE: 4502), has submitted a New Drug Application to the Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone (CLD) for the treatment of hypertension. 25 February 2011
Pharmaceutical
A research team, led by USA-based La Jolla Institute scientist Joel Linden, has shed new light on the problem of insulin resistance, and identified the key participants in a molecular pathway that holds therapeutic promise for reducing the severity of type 2 diabetes. 25 February 2011
Pharmaceutical
The US Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the Onglyza (saxagliptin) US Prescribing Information for adult type 2 diabetes patients. The drug is marketed by Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb (NYSE: BMY). 24 February 2011
Biotechnology
India's Wockhardt (BSE: WOCK) says that it has formed a strategic alliance with Sheffield Bio-Science, a subsidiary of USA-based Kerry Group, which will become the exclusive global sales and distribution partner for its recombinant insulin. According to estimates, the potential in cell culture markets is around $50 million. 22 February 2011
Pharmaceutical
Patients with both type 1 diabetes and chronic kidney disease (CKD) have an increased risk of adverse outcomes. Despite aggressive treatment, many patients with type 1 diabetes and overt nephropathy develop end-stage renal disease (ESRD) and/or succumb to a premature death. The competing risks of death and ESRD may confound the estimates of risk for each outcome. 22 February 2011
Pharmaceutical
Danish insulin giant Novo Nordisk says it has received a subpoena from the office of the US Attorney for the District of Massachusetts calling for the production of documents regarding potential criminal offences relating to the company's marketing and promotion practices for its diabetes treatments NovoLog (insulin aspart [rDNA origin] injection), Levemir (insulin detemir [rDNA origin] injection) and Victoza (liraglutide). 16 February 2011
Pharmaceutical
Researchers at the Children's Hospital Boston in the USA have discovered a mechanism for normalizing blood sugar that does not involve insulin and could offer a new therapeutic approach to both kinds of diabetes. 16 February 2011
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze